• KU Leuven, of Belgium, and FIT Biotech Oyj plc, of Tampere, Finland, signed a worldwide license and collaboration agreement to develop immunotherapeutics based on FIT's Gene Transport Unit technology for transient in vivo expression of monoclonal antibodies.